Saluda Medical Launches CAP24 Surgical Paddle Lead Across US Following FDA Approval
MT Newswires Live
Oct 06
Saluda Medical (ASX:SLD) began the full US commercial release of its CAP24 surgical paddle lead following US Food and Drug Administration approval earlier this year, according to a Tuesday Australian bourse filing.
The paddle lead is now available to neurosurgery and orthopedic spine practices across the US, expanding access to the surgical segment, the company said.
The company said CAP24 is the first and only FDA-approved surgical paddle lead purpose-built for physiologic, dose-controlled closed-loop therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.